Squalamine eye drops for wet macular degeneration

- Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions - http://eyedocnews.com -

Ohr Pharmaceutical Announces Positive Preclinical Safety Study Results for Squalamine Eye Drop for Wet-AMD

Posted By Dr. Ari Weitzner On July 13, 2012 @ 5:45 am In Macular Degeneration,New Technologies | Comments Disabled

We’ve previously blogged about the Squalamine eye drops ^[1] being developed by Ohr Pharmaceutical (OCTBB: OHRP) for treatment of wet AMD.

Earlier this week, OHRP announced positive results from a long term safety study of Squalamine eye drops, which indicated that the eye drop is safe when applied to the eye with no signs of ocular or systemic toxicity on long term administration.

Obviously, an eye drop for wet-AMD would be a “game changer” for patients currently requiring regular injections of Lucentis, Avastin or Eylea directly into the eye. So we’ll keep you posted on developments of this novel eye drop.

Click here ^[2] to read the full press release.

Article printed from Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions: http://eyedocnews.com

URL to article: http://eyedocnews.com/006721-ohr-pharmaceutical-announces-positive-preclinical-safety-study-results-for-squalamine-eye-drop-for-wet-amd/

URLs in this post:

[1] Squalamine eye drops: http://eyedocnews.com/006675-eye-drop-to-treat-wet-macular-degeneration-granted-fast-track-designation-by-fda/

[2] Click here: http://finance.yahoo.com/news/ohr-pharmaceutical-announces-positive-preclinical-140000555.html

Click here to print.